Analytic Investors’s Biogen BIIB Stock Holding History

Analytic Investors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-25,025	Closed	-$7.67M	–	605
2015 Q4	$7.67M	Buy	25,025 +11,081	+79%	+$3.18M	0.1%	176
2015 Q3	$4.07M	Buy	13,944 +3,322	+31%	+$1.1M	0.05%	204
2015 Q2	$4.29M	Sell	10,622 -12,909	-55%	-$5.18M	0.06%	185
2015 Q1	$9.94M	Buy	23,531 +9,869	+72%	+$3.89M	0.14%	129
2014 Q4	$4.64M	Sell	13,662 -55,908	-80%	-$18.1M	0.07%	178
2014 Q3	$23M	Buy	69,570 +47,882	+221%	+$15.8M	0.33%	94
2014 Q2	$6.84M	Sell	21,688 -8,737	-29%	-$2.63M	0.11%	150
2014 Q1	$9.31M	Sell	30,425 -7,900	-21%	-$2.51M	0.14%	147
2013 Q4	$10.7M	Buy	38,325 +36,647	+2,184%	+$9.48M	0.18%	126
2013 Q3	$404K	Sell	1,678 -1,767	-51%	-$395K	0.01%	410
2013 Q2	$741K	Buy	+3,445	New	+$736K	0.01%	390

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Analytic Investors's BIIB Position: Q1 2016 in Review

Analytic Investors sold out of Biogen (BIIB) in Q1 2016, closing a stake of 25,025 shares — an estimated $7.67M sold.

Analytic Investors first reported a position in BIIB in Q2 2013 and held it in 11 quarters. The position peaked at $23M in Q3 2014. 948 funds tracked by Wall St. Rank hold BIIB as of Q1 2016.

Analytic Investors reported no remaining Biogen position as of Q1 2016 after selling out during the quarter.
Analytic Investors sold 25,025 Biogen shares in Q1 2016, an estimated $7.67M.
Analytic Investors first reported a position in Biogen in Q2 2013 and held it in 11 quarters.
Analytic Investors's Biogen position peaked at $23M in Q3 2014.
948 funds tracked by Wall St. Rank held Biogen as of Q1 2016.

Based on Analytic Investors's 13F filing for Q1 2016, filed 20 May 2016.